Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine | Australian Government Department of Health and Aged Care
COVID-19 bivalent booster effectiveness in people with and without immune dysfunction L
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv
Real-world data show new Covid boosters increase protection
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Why payers should be preparing now for new COVID-19 boosters
Let's discuss COVID-19 Bivalent Booster Effectiveness - ICAP
The bivalent vaccine booster outperforms - by Eric Topol
Who Is Eligible for a COVID-19 Booster?
NEJM on X: "Figure 1. Effectiveness of Bivalent Boosters According to the Interval since Administration. https://t.co/hIVtIujZoq #Covid19 https://t.co/KBljA6y7NR" / X
New Omicron-specific vaccines offer similar protection to existing boosters
Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog
Why and When to Get a Bivalent Covid-19 Booster | Johns Hopkins | Bloomberg School of Public Health
What We Know About Getting a Second Booster Shot of COVID-19 Vaccines | The Scientist Magazine®
A quick update on the bivalent boosters - by Eric Topol
DPH Shares Monthly COVID-19 Update, Announces Changes to Data Reporting and Booster Guidance - State of Delaware News
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age | medRxiv
COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - CROI Conference
CDC reports on bivalent COVID-19 vaccine, Paxlovid effectiveness | AHA News
